See more : Cirrus Logic, Inc. (CRUS) Income Statement Analysis – Financial Results
Complete financial analysis of Medicus Pharma Ltd. Common Stock (MDCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicus Pharma Ltd. Common Stock, a leading company in the None industry within the None sector.
You may be interested
- Jyske Invest Virksomhedsobligationer Inc KL (JYIVIRK.CO) Income Statement Analysis – Financial Results
- Elvictor Group, Inc. (ELVG) Income Statement Analysis – Financial Results
- Eurofins-Cerep SA (ALECR.PA) Income Statement Analysis – Financial Results
- Glow Holdings, Inc. (GLOH) Income Statement Analysis – Financial Results
- Namsung Corp. (004270.KS) Income Statement Analysis – Financial Results
Medicus Pharma Ltd. Common Stock (MDCX)
Unable to fetch income statement for: MDCX
Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with more than 25% of the 60 patients expected to be enrolled in...
Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The collaboration aims to identify potential...
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus"...
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in...
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program
Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trial - ICYMI
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari joined Proactive to discuss the company's recent listing on the Nasdaq, a key milestone for the biotechnology firm. Following their initial public offering (IPO) on the Nasdaq, Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX)...
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a...
Medicus Pharma announces pricing of US IPO
Medicus Pharma (TSX-V:MDCX) announced the pricing of its US initial public offering (IPO), with 970,000 units priced at $4.125 per unit. Each unit will comprise one common share and one warrant, which are exercisable at $4.64 and have a five-year...
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public offering in the United States of 970,000 units, at a price of...
Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing
Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") today announced that it has completed a consolidation of its common shares on a 2-to-1 basis (the "Consolidation").
Source: https://incomestatements.info
Category: Stock Reports